Immix Biopharma, Inc.
IMMX
$2.03
-$0.065-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.61M | 2.95M | 2.48M | 2.34M | 2.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.99M | 7.39M | 4.70M | 5.59M | 5.38M |
| Operating Income | -4.99M | -7.39M | -4.70M | -5.59M | -5.38M |
| Income Before Tax | -4.80M | -7.14M | -4.40M | -5.32M | -5.15M |
| Income Tax Expenses | 10.80K | 11.10K | 10.30K | 8.80K | 8.10K |
| Earnings from Continuing Operations | -4.81M | -7.15M | -4.41M | -5.33M | -5.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -- | 12.90K | 72.10K | 65.90K |
| Net Income | -4.81M | -7.15M | -4.39M | -5.26M | -5.09M |
| EBIT | -4.99M | -7.39M | -4.70M | -5.59M | -5.38M |
| EBITDA | -4.97M | -7.39M | -4.70M | -5.59M | -5.37M |
| EPS Basic | -0.16 | -0.24 | -0.15 | -0.22 | -0.23 |
| Normalized Basic EPS | -0.10 | -0.15 | -0.10 | -0.14 | -0.14 |
| EPS Diluted | -0.16 | -0.24 | -0.15 | -0.22 | -0.23 |
| Normalized Diluted EPS | -0.10 | -0.15 | -0.10 | -0.14 | -0.14 |
| Average Basic Shares Outstanding | 29.56M | 29.42M | 28.79M | 23.44M | 21.78M |
| Average Diluted Shares Outstanding | 29.56M | 29.42M | 28.79M | 23.44M | 21.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |